Skip to content
ClinCalc Pro
Menu
Dihydropyridine calcium-channel blocker

Lacidipine

Brand names: Motens

Lacidipine is a dihydropyridine calcium-channel blocker used in the treatment of hypertension.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively blocks L-type calcium channels in vascular smooth muscle, causing arterial vasodilatation that reduces peripheral vascular resistance and lowers blood pressure.

Prescribing in practice

  • Vasodilatory effects such as ankle oedema, flushing, headache and palpitations are common and may limit treatment.
  • Use with caution in significant hepatic impairment, which can increase exposure to the drug.
  • It is contraindicated in patients with hypersensitivity to dihydropyridines, and caution is needed in unstable or significant aortic stenosis.

Monitoring

Monitor blood pressure for response and review the patient for dose-related ankle swelling and other vasodilatory effects.

Counselling the patient

  • Ankle swelling, flushing or headache may occur, particularly early in treatment.
  • Report palpitations or significant dizziness.
  • Continue taking the medicine regularly even when you feel well, as it controls rather than cures high blood pressure.

Evidence & guidelines

Dihydropyridine calcium-channel blockers are a recommended class for hypertension in NICE guidance, with established blood-pressure-lowering efficacy.

Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.